To Bioprint or Not to Bioprint

Tran, Jasper L.

doi:10.31228/osf.io/dxktj

Cited by 7 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are concerns that while bioprinting is regulated by existing laws that govern medicine and medical research, this current framework does not allow us to mitigate risks to patients, as well as address the requirements of health-care providers and manufacturers. At the very least, that is the situation in the US and EU[ 66 ]. There is no specific regulatory framework or even strategy toward 3D bioprinting developed in countries that lead the way in biofabrication research and industry applications.…”

Section: Drug Discoverymentioning

confidence: 99%

3D Bioprinting: The Roller Coaster Ride to Commercialization

Elemoso¹,

Shalunov²,

Balakhovsky³

et al. 2020

IJB

View full text Add to dashboard Cite

Three-dimensional (3D) bioprinting as a technology is being researched and applied since 2003. It is actually several technologies (inkjet, extrusion, laser, magnetic bioprinting, etc.) under an umbrella term “3D bioprinting.” The versatility of this technology allows widespread applications in several; however, after almost 20 years of research, there is still a limited number of cases of commercialized applications. This article discusses the potential for 3D bioprinting in regenerative medicine, drug discovery, and food industry, as well as the existing cases of companies that create commercialized products and services in the aforementioned areas and even in fashion, including their go-to-market route and financing received. We also address the main barriers to creating practical applications of 3D bioprinting within each sphere the technology that is being studied for.

show abstract

Section: Drug Discoverymentioning

confidence: 99%

3D Bioprinting: The Roller Coaster Ride to Commercialization

Elemoso¹,

Shalunov²,

Balakhovsky³

et al. 2020

IJB

View full text Add to dashboard Cite

show abstract

“…Legal offerings suggest that bioprinting enters new territory distinct from previous legal regulation on medicine or on conventional 3D printing in relation to legal ideas of the body and the rights and responsibilities held by different groups. 9 10 12 13 Harbaugh 9 focuses mainly on issues around ownership and the potential value of bioprinting products to different interested parties, including physicians, researchers and biotechnology companies. This is accompanied by a duty, however, to maintain the patients’ autonomy over their bodies.…”

Section: Bioprinting—ethical Challengesmentioning

confidence: 99%

“…This is accompanied by a duty, however, to maintain the patients’ autonomy over their bodies. It is similarly suggested by Tran 12 that benefits of bioprinting outweigh what he considers to be comparatively low risks, but that joint regulation between the medical and legal professions is needed to prevent new forms of exploitation such as a new black market in biofabricated organs.…”

Section: Bioprinting—ethical Challengesmentioning

confidence: 99%

3D bioprint me: a socioethical view of bioprinting human organs and tissues

et al. 2017

View full text Add to dashboard Cite

In this article, we review the extant social science and ethical literature on three-dimensional (3D) bioprinting. 3D bioprinting has the potential to be a ‘game-changer’, printing human organs on demand, no longer necessitating the need for living or deceased human donation or animal transplantation. Although the technology is not yet at the level required to bioprint an entire organ, 3D bioprinting may have a variety of other mid-term and short-term benefits that also have positive ethical consequences, for example, creating alternatives to animal testing, filling a therapeutic need for minors and avoiding species boundary crossing. Despite a lack of current socioethical engagement with the consequences of the technology, we outline what we see as some preliminary practical, ethical and regulatory issues that need tackling. These relate to managing public expectations and the continuing reliance on technoscientific solutions to diseases that affect high-income countries. Avoiding prescribing a course of action for the way forward in terms of research agendas, we do briefly outline one possible ethical framework ‘Responsible Research Innovation’ as an oversight model should 3D bioprinting promises are ever realised. 3D bioprinting has a lot to offer in the course of time should it move beyond a conceptual therapy, but is an area that requires ethical oversight and regulation and debate, in the here and now. The purpose of this article is to begin that discussion.

show abstract

“…3D PRINTING ¶4 3D printing 13 simply adds another dimension to 2D printing. 14 That is, 3D printing essentially stacks multiple layers of 2D printing on top of one another to reproduce a threedimensional object following an electronic blueprint called a "Computer-Aided Design file" (or "CAD file"). 15 Like Star Trek's Replicator, 16 current 3D printers can print in materials like plastic, metal, ceramic, cement, wood, food, and human cells.…”

Section: The Printing Press ¶3mentioning

confidence: 99%